Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment
Authors:
- S. MichelsSMS. Michels
- W. GeitzenauerWGW. Geitzenauer
- F. PragerFPF. Prager
- U. Schmidt-ErfurthUSU. Schmidt-Erfurth
- 18 October 2006
- journal article
- clinical trial
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (6) , 785-789
Abstract
To evaluate the effect of systemic bevacizumab (Avastin) therapy on pigment epithelial detachment (PED) secondary to age-related macular degeneration (AMD) and to identify prognostic factors for PED regression and improvement in best corrected visual acuity (BCVA). Prospective uncontrolled pilot study. Nine patients (nine eyes) received three systemic bevacizumab treatments at 2 week intervals and were examined at baseline, weeks 1, 2, 4, 6 and month 3 by using optical coherence tomography (Stratus OC, Carl Zeiss Meditec, Dublin, California, USA). Changes in maximum PED height and greatest linear diameter (GLD) were planimetrically analysed by using Adobe Photoshop CS and correlated with retinal morphological changes and changes in BCVA. Systemic bevacizumab therapy was well tolerated. Mean maximum PED height decreased significantly by 21% as early as 1 week (-96 microm (SD 48.8), p<0.01). At 3 months follow-up, two PEDs resolved completely, mean maximum PED height decreased significantly by 39% (-179 microm (SD 178), p = 0.02) and mean PED GLD by 24% (-714 microm (SD 1010), p = 0.07). Mean BCVA improved significantly by week 2 (+8.7 letters (SD 5.7), p<0.01) and at 3 months with 12.7 letters (SD 6.4) (p<0.01). In the examined nine patients, systemic bevacizumab therapy showed evidence for an effect on PED secondary to neovascular AMD in terms of a decrease in lesion height and diameter. A high PED at baseline was found to be a negative predictive factor for visual outcome.Keywords
This publication has 23 references indexed in Scilit:
- INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Vascular Endothelial Growth Factor: Basic Science and Clinical ProgressEndocrine Reviews, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Photodynamic Therapy for Occult Choroidal Neovascularization With PigmentEpithelium Detachment in Age-Related Macular DegenerationArchives of Ophthalmology (1950), 2004
- The epidemiology of age-related macular degenerationAmerican Journal of Ophthalmology, 2004
- Potential Public Health Impact of Age-Related Eye Disease Study ResultsArchives of Ophthalmology (1950), 2003
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- Vascular Endothelial Growth Factor Family and Receptor Expression in Human Choroidal Neovascular MembranesMicrovascular Research, 2002
- Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor.1996
- Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes.1996